FCGR2A and hepatocellular carcinoma: Collectively, this study integrates multi-omics and functional validation to define FCGR2A as a mechanistically interpretable biomarker linking immune activation with clinical outcomes, offering potential guidance for personalized immunotherapy and advancing precision oncology in HCC.